摘要
目的评价无抽搐电休克（MECT）治疗难治性精神分裂症的临床疗效。方法选择2010年6月至2011年6月期间我院收治的100例难治性精神分裂症患者，应用抗精神病药合并MECT治疗。应用阳性和阴性症状量表（PANSS）评估临床疗效，采用副反应量表（TESS）评定不良反应。结果本组患者经合并MECT治疗1、4及8周后有效率分别为9％、29％、56％。与合并MECT治疗前比较，治疗4周、8周后PANSS总分、阳性症状、阴性症状及一般精神病理分均显著降低（P〈0．05或P〈0．01）。不同治疗时段TESS总分均较治疗前降低，但差异比较均无统计学意义（P〉0．05）。治疗过程中不良反应均较轻微，不影响治疗。结论抗精神病药合并MECT治疗难治性精神分裂症的临床疗效确切，未增加副反应，是治疗难治l生精神分裂症的有效方法。
Objective To evaluate the clinical efficacy of modified electroconvulsive therapy （ MECT ） for refractory schizophrenia. Methods 100 patients with refractory schizophrenia who had been hospitalized during the period of June 2010 to June 2011 were treated with antipsychotic medication and MECT. The Positive and Negative Syndrome Scale （ PANSS ）were used to evaluate the clinical effect and the Treatment Emergent Symptom Scale （ TESS ） was used to determine adverse reactions. Results The effective rate was 9% on week 1, 29% on week 4, and 56% on week 8. The total scores on the PANSS, positive symptoms, negative symptoms, and general psychopathologic scores were significantly decreased on weeks 4 and 8 （ P〈0.05 or P〈0.01 ）. There was no statistical difference in the scores on the TESS （ P〉 0.05 ）. Adverse reactions occurred slightly during treatment. Conclusions Antipsychotic medication com- bined with modified electroconvulsive therapy is effective for refractory schizophrenia without increased adverse reactions.
出处
《国际医药卫生导报》
2012年第15期2248-2250,共3页
International Medicine and Health Guidance News
